Stock Analiz

Apyx Medical Corp APYX

Medical/Dental Instruments · data as of November 13, 2026

$2.81Market cap $118M
Open the interactive analysis →

Apyx Medical Corp (APYX) is a healthcare company listed in the US with a market value of about $118M. In the twelve months to September 30, 2026 it had revenue of $60M and net income of -$8M, a net margin of -14.2%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 14% a year, a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 81% below the current price.

About Apyx Medical

Apyx Medical is listed in the US and classified in medical/dental instruments. Revenue went from $9M in 2016 to $53M in 2025, growth of about 22.0% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 19% over three years (dilution for shareholders). It spends 6% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.0
P/B12.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-7.5%
Shareholder yield0.0%
Intrinsic value vs. price−81%

Growth and quality

Revenue growth (1 yr)9.9%
Revenue growth (5 yrs, per year)13.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-37.8%
ROIC (5-yr avg.)-25.4%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$60M$53M$48M$52M$45M$49M$28M$28M—$10M$9M
Net income-$8M-$11M-$23M-$19M-$23M-$15M-$12M-$20M$63M-$5M-$12M
Free cash flow-$9M-$9M-$19M-$6M-$21M-$11M-$17M-$20M-$21M-$4M-$3M
EPS (diluted)$-0.19$-0.27$-0.66$-0.54$-0.67$-0.44$-0.35$-0.58$1.83$-0.17$-0.15
Net margin-14.2%-21.2%-48.8%-35.8%-52.1%-31.3%-42.9%-69.8%—-49.5%-131.0%
ROIC—-9.0%-26.3%-22.0%-48.6%-21.2%-19.3%-28.9%-12.0%-55.5%-30.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Apyx Medical stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 81% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Apyx Medical pay a dividend?

Not currently.

Is Apyx Medical a good stock to buy?

We do not give buy or sell advice. Apyx Medical scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.